OncRef

Clinical Trial: NCT05153239

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:PharmaMar
Information Provided By:PharmaMar
Last Update Posted:2026-10-21

Study Overview

Brief Summary

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.

Official Title

A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)

Conditions

Relapsed Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Irinotecan
  • Drug: Lurbinectedin
  • Drug: Irinotecan
  • Drug: Topotecan
  • Drug: Lurbinectedin

Other Study ID Numbers

  • PM1183-C-008-21

Start Date (Actual)

2022-07-22

Primary Completion Date (Actual)

2026-04-10

Study Completion Date (Actual)

2026-04-10

Enrollment (Actual)

705

Study Type

Interventional

Phase

Phase 3